# Jessica Zucman-Rossi

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 394 papers | 50,040 citations | 3333 91 h-index | 1713 213 g-index |
| 420 all docs | 420 docs citations | 420 times ranked | 51377 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421. | 13.7 | 8,060 |
| 2 | Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6. | 18.1 | 2,757 |
| 3 | International network of cancer genome projects. Nature, 2010, 464, 993-998. | 13.7 | 2,114 |
| 4 | Hepatocellular carcinoma. Nature Reviews Disease Primers, 2016, 2, 16018. | 18.1 | 1,863 |
| 5 | Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature, 1992, 359, 162-165. | 13.7 | 1,724 |
| 6 | Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genetics, 2015, 47, 505-511. | 9.4 | 1,372 |
| 7 | Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature, 1993, 363, 515-521. | 13.7 | 1,351 |
| 8 | Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature Genetics, 2012, 44, 694-698. | 9.4 | 1,229 |
| 9 | Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology, 2007, 45, 42-52. | 3.6 | 1,034 |
| 10 | The Ewing Family of Tumors -- A Subgroup of Small-Round-Cell Tumors Defined by Specific Chimeric Transcripts. New England Journal of Medicine, 1994, 331, 294-299. | 13.9 | 1,010 |
| 11 | Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 1226-1239.e4. | 0.6 | 980 |
| 12 | Genotypeâ€“phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. Hepatology, 2006, 43, 515-524. | 3.6 | 733 |
| 13 | Mechanisms of HBV-induced hepatocellular carcinoma. Journal of Hepatology, 2016, 64, S84-S101. | 1.8 | 664 |
| 14 | MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology, 2008, 47, 1955-1963. | 3.6 | 634 |
| 15 | Toward understanding and exploiting tumor heterogeneity. Nature Medicine, 2015, 21, 846-853. | 15.2 | 604 |
| 16 | Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology, 2007, 46, 740-748. | 3.6 | 554 |
| 17 | Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 5752-5756. | 3.3 | 538 |
| 18 | A gp130â€“Srcâ€“YAP module links inflammation to epithelial regeneration. Nature, 2015, 519, 57-62. | 13.7 | 528 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. Journal of Hepatology, 2017, 67, 727-738. | 1.8 | 525 |
| 20 | High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nature Communications, 2013, 4, 2218. | 5.8 | 513 |
| 21 | EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nature Genetics, 1993, 4, 341-345. | 9.4 | 483 |
| 22 | Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature, 2009, 457, 200-204. | 13.7 | 437 |
| 23 | Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience. Hepatology, 2009, 50, 481-489. | 3.6 | 394 |
| 24 | Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nature Genetics, 2015, 47, 1187-1193. | 9.4 | 387 |
| 25 | EASL Clinical Practice Guidelines on the management of benign liver tumours. Journal of Hepatology, 2016, 65, 386-398. | 1.8 | 372 |
| 26 | DNA methylationâ€based prognosis and epidrivers in hepatocellular carcinoma. Hepatology, 2015, 61, 1945-1956. | 3.6 | 367 |
| 27 | GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. Journal of Hepatology, 2012, 56, 184-191. | 1.8 | 354 |
| 28 | Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. Hepatology, 2014, 60, 1972-1982. | 3.6 | 345 |
| 29 | Bi-allelic inactivation of TCF1 in hepatic adenomas. Nature Genetics, 2002, 32, 312-315. | 9.4 | 333 |
| 30 | Molecular and histological correlations in liver cancer. Journal of Hepatology, 2019, 71, 616-630. | 1.8 | 308 |
| 31 | Genetics of hepatocellular tumors. Oncogene, 2006, 25, 3778-3786. | 2.6 | 304 |
| 32 | A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. Gastroenterology, 2013, 145, 176-187. | 0.6 | 302 |
| 33 | Molecular Classification of Hepatocellular Adenoma AssociatesÂWith Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology, 2017, 152, 880-894.e6. | 0.6 | 290 |
| 34 | Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes and Cancer, 1992, 5, 271-277. | 1.5 | 284 |
| 35 | Hepatocellular adenomas: Magnetic resonance imaging features as a function of molecular pathological classification. Hepatology, 2008, 48, 808-818. | 3.6 | 277 |
| 36 | Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology, 2014, 60, 1983-1992. | 3.6 | 268 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Hepatocellular Benign Tumorsâ€"From Molecular Classification to Personalized Clinical Care. Gastroenterology, 2013, 144, 888-902. | 0.6 | 251 |
| 38 | Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. Clinical Cancer Research, 2015, 21, 1329-1339. | 3.2 | 250 |
| 39 | cHCCâ€CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 2018, 68, 113-126. | 3.6 | 244 |
| 40 | Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. Cancer Cell, 2014, 25, 428-441. | 7.7 | 240 |
| 41 | Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. Journal of Hepatology, 2008, 48, 163-170. | 1.8 | 235 |
| 42 | Differential effects of inactivated Axin1 and activated Î²-catenin mutations in human hepatocellular carcinomas. Oncogene, 2007, 26, 774-780. | 2.6 | 230 |
| 43 | Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nature Communications, 2017, 8, 1315. | 5.8 | 228 |
| 44 | Genotypeâ€phenotype correlation of CTNNB1 mutations reveals different ÃŸâ€catenin activity associated with liver tumor progression. Hepatology, 2016, 64, 2047-2061. | 3.6 | 222 |
| 45 | Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 58-65. | 1.8 | 219 |
| 46 | Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. Journal of Experimental Medicine, 2011, 208, 1359-1366. | 4.2 | 218 |
| 47 | High Incidence of Activating <scp>TERT</scp> Promoter Mutations in Meningiomas Undergoing Malignant Progression. Brain Pathology, 2014, 24, 184-189. | 2.1 | 209 |
| 48 | Clinical, Morphologic, and Molecular Features Defining So-Called Telangiectatic Focal Nodular Hyperplasias of the Liver. Gastroenterology, 2005, 128, 1211-1218. | 0.6 | 207 |
| 49 | A MYCâ€"aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nature Medicine, 2016, 22, 744-753. | 15.2 | 207 |
| 50 | PNPLA3 gene in liver diseases. Journal of Hepatology, 2016, 65, 399-412. | 1.8 | 205 |
| 51 | Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Human Molecular Genetics, 1995, 4, 2219-2226. | 1.4 | 190 |
| 52 | Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification. Hepatology, 2013, 58, 229-238. | 3.6 | 172 |
| 53 | Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. Journal of Hepatology, 2007, 46, 521-527. | 1.8 | 170 |
| 54 | Familia liver adenomatosis associated with hepatocyte nuclear factor 1Î± inactivation1 1The authors thank Leigh Pascoe for critical reading of the manuscript, HÃ©lÃ¨ne BlanchÃ© and Hung Bui of the CEPH/Fondation Jean Dausset for technical help in sequencing, and Drs. A. Saillant, E. Akodjenou, and E. Urvoas (Pediatric and Radiology Units, HÃ´pitaux de Chartres, France) for referring patient B1 to E.J. and for performing liver ultrasound screening in family B.. Gastroenterology, 2003, 125, 1470-1475. | 0.6 | 169 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Advances in Immunology, 2016, 130, 95-190. | 1.1 | 160 |
| 56 | Macrotrabecularâ€massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology, 2018, 68, 103-112. | 3.6 | 159 |
| 57 | The role of telomeres and telomerase in cirrhosis and liver cancer. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 544-558. | 8.2 | 154 |
| 58 | Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell, 2018, 33, 1061-1077.e6. | 7.7 | 151 |
| 59 | Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene, 1999, 18, 4044-4046. | 2.6 | 149 |
| 60 | High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Human Molecular Genetics, 2001, 10, 271-282. | 1.4 | 147 |
| 61 | Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. Journal of Hepatology, 2013, 58, 350-357. | 1.8 | 146 |
| 62 | Loss of Trim24 (Tif1Î±) gene function confers oncogenic activity to retinoic acid receptor alpha. Nature Genetics, 2007, 39, 1500-1506. | 9.4 | 145 |
| 63 | Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology, 2019, 156, 492-509. | 0.6 | 145 |
| 64 | Overâ€expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver International, 2009, 29, 459-465. | 1.9 | 143 |
| 65 | Subtype Classification of Hepatocellular Adenoma. Digestive Surgery, 2010, 27, 39-45. | 0.6 | 143 |
| 66 | Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology, 2019, 157, 760-776. | 0.6 | 141 |
| 67 | Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. Journal of Hepatology, 2012, 57, 663-674. | 1.8 | 140 |
| 68 | Genetics of Hepatobiliary Carcinogenesis. Seminars in Liver Disease, 2011, 31, 173-187. | 1.8 | 138 |
| 69 | Mutational signature analysis identifies <scp>MUTYH</scp> deficiency in colorectal cancers and adrenocortical carcinomas. Journal of Pathology, 2017, 242, 10-15. | 2.1 | 130 |
| 70 | Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology, 2020, 71, 164-182. | 3.6 | 129 |
| 71 | Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut, 2015, 64, 820-829. | 6.1 | 127 |
| 72 | Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. Journal of Hepatology, 2004, 41, 292-298. | 1.8 | 126 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood, 2002, 100, 991-997. | 0.6 | 125 |
| 74 | Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nature Communications, 2019, 10, 1333. | 5.8 | 125 |
| 75 | Hepatocyte Nuclear Factor-1Î± Gene Inactivation: Cosegregation between Liver Adenomatosis and Diabetes Phenotypes in Two Maturity-Onset Diabetes of the Young (MODY)3 Families. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1476-1480. | 1.8 | 124 |
| 76 | HNF1Î± Inactivation Promotes Lipogenesis in Human Hepatocellular Adenoma Independently of SREBP-1 and Carbohydrate-response Element-binding Protein (ChREBP) Activation. Journal of Biological Chemistry, 2007, 282, 14437-14446. | 1.6 | 123 |
| 77 | Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2014, 20, 1323-1334. | 3.2 | 121 |
| 78 | Molecular classification of hepatocellular adenoma in clinical practice. Journal of Hepatology, 2017, 67, 1074-1083. | 1.8 | 119 |
| 79 | Immunohistochemical Markers on Needle Biopsies Are Helpful for the Diagnosis of Focal Nodular Hyperplasia and Hepatocellular Adenoma Subtypes. American Journal of Surgical Pathology, 2012, 36, 1691-1699. | 2.1 | 118 |
| 80 | Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nature Communications, 2018, 9, 5235. | 5.8 | 118 |
| 81 | Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Annals of Oncology, 2011, 22, 794-800. | 0.6 | 116 |
| 82 | RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. Cancer Cell, 2017, 31, 94-109. | 7.7 | 115 |
| 83 | Revisiting the Pathology of Resected Benign Hepatocellular Nodules Using New Immunohistochemical Markers. Seminars in Liver Disease, 2011, 31, 091-103. | 1.8 | 112 |
| 84 | Germline hepatocyte nuclear factor 1Î± and 1Î² mutations in renal cell carcinomas. Human Molecular Genetics, 2005, 14, 603-614. | 1.4 | 109 |
| 85 | Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 806-818.e10. | 0.6 | 109 |
| 86 | Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut, 2022, 71, 616-626. | 6.1 | 106 |
| 87 | Genomic Profiling Reveals Alternative Genetic Pathways of Meningioma Malignant Progression Dependent on the Underlying NF2 Status. Clinical Cancer Research, 2010, 16, 4155-4164. | 3.2 | 103 |
| 88 | Trial Watch: Monoclonal antibodies in cancer therapy. OncoImmunology, 2012, 1, 28-37. | 2.1 | 103 |
| 89 | Chromosome translocation based on illegitimate recombination in human tumors. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11786-11791. | 3.3 | 101 |
| 90 | Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology, 2007, 46, 1108-1118. | 3.6 | 100 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Inactivation of theAPCGene Is Constant in Adrenocortical Tumors from Patients with Familial Adenomatous Polyposis but Not Frequent in Sporadic Adrenocortical Cancers. Clinical Cancer Research, 2010, 16, 5133-5141. | 3.2 | 97 |
| 92 | Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics, 1993, 18, 609-615. | 1.3 | 94 |
| 93 | Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and pointâ€mutant Î²â€catenin. Hepatology, 2016, 64, 1587-1605. | 3.6 | 92 |
| 94 | Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by Î²-Catenin Mutations. Cell Metabolism, 2019, 29, 1135-1150.e6. | 7.2 | 92 |
| 95 | Genotype phenotype classification of hepatocellular adenoma. World Journal of Gastroenterology, 2007, 13, 2649. | 1.4 | 90 |
| 96 | Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. British Journal of Cancer, 2013, 108, 887-900. | 2.9 | 88 |
| 97 | The Î²-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. Journal of Hepatology, 2008, 49, 61-71. | 1.8 | 87 |
| 98 | microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis. Gastroenterology, 2018, 155, 1951-1966.e26. | 0.6 | 86 |
| 99 | Polyploidy spectrum: a new marker in HCC classification. Gut, 2020, 69, 355-364. | 6.1 | 82 |
| 100 | Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology, 2018, 155, 431-442.e10. | 0.6 | 81 |
| 101 | Dual Targeting of Histone Methyltransferase G9a and DNAâ€Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. Hepatology, 2019, 69, 587-603. | 3.6 | 81 |
| 102 | Hepatocellular adenoma: what is new in 2008. Hepatology International, 2008, 2, 316-321. | 1.9 | 78 |
| 103 | TERT promoter mutations in primary liver tumors. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 9-14. | 0.7 | 78 |
| 104 | AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of Î²-catenin activation. Journal of Hepatology, 2018, 68, 1203-1213. | 1.8 | 78 |
| 105 | Adeno-associated virus in the liver: natural history and consequences in tumour development. Gut, 2020, 69, 737-747. | 6.1 | 78 |
| 106 | KIF20A mRNA and Its Product MKlp2 Are Increased During Hepatocyte Proliferation and Hepatocarcinogenesis. American Journal of Pathology, 2012, 180, 131-140. | 1.9 | 76 |
| 107 | A functional screening identifies five micrornas controlling glypican-3: role of mir-1271 down-regulation in hepatocellular carcinoma. Hepatology, 2013, 57, 195-204. | 3.6 | 76 |
| 108 | Identification of Novel Oncogenes and Tumor Suppressors in Hepatocellular Carcinoma. Seminars in Liver Disease, 2010, 30, 075-086. | 1.8 | 75 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | A 17â€Betaâ€Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. Hepatology, 2019, 70, 231-240. | 3.6 | 75 |
| 110 | From the Editorâ€™s desk..... Journal of Hepatology, 2018, 69, 1-4. | 1.8 | 74 |
| 111 | Genetic alterations of malignant pleural mesothelioma: associationÂwith tumor heterogeneity and overall survival. Molecular Oncology, 2020, 14, 1207-1223. | 2.1 | 74 |
| 112 | Molecular classification of hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, S235-S241. | 0.4 | 73 |
| 113 | Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. European Urology, 2018, 74, 474-480. | 0.9 | 72 |
| 114 | PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. International Journal of Cancer, 2019, 144, 533-544. | 2.3 | 72 |
| 115 | Recurrent inactivating mutations of ARID2 in nonâ€small cell lung carcinoma. International Journal of Cancer, 2013, 132, 2217-2221. | 2.3 | 70 |
| 116 | Cloning of a balanced translocation breakpoint in the DiGeorge syndrome critical region and isolation of a novel potential adhesion receptor gene in its vicinity. Human Molecular Genetics, 1995, 4, 551-558. | 1.4 | 69 |
| 117 | NF2 gene in neurofibromatosis type 2 patients. Human Molecular Genetics, 1998, 7, 2095-2101. | 1.4 | 69 |
| 118 | CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. European Journal of Cancer, 2012, 48, 138-148. | 1.3 | 68 |
| 119 | Prognostic impact of baseline serum <scp>C</scp>â€reactive protein in patients with metastatic renal cell carcinoma (<scp>RCC</scp>) treated with sunitinib. BJU International, 2014, 114, 81-89. | 1.3 | 68 |
| 120 | Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene, 2014, 33, 3748-3752. | 2.6 | 68 |
| 121 | Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes. Cancer Genetics and Cytogenetics, 1994, 74, 13-18. | 1.0 | 67 |
| 122 | Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma. Clinical Cancer Research, 2017, 23, 3191-3202. | 3.2 | 67 |
| 123 | Loss of hepatocyte nuclear factor 1Î± function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology, 2010, 51, 557-566. | 3.6 | 66 |
| 124 | A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression. Journal of the National Cancer Institute, 2011, 103, 47-60. | 3.0 | 66 |
| 125 | Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. Hepatology, 2021, 73, 14-26. | 3.6 | 66 |
| 126 | Nivolumab, nivolumabâ€“ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 612-624. | 5.1 | 66 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene, 2002, 21, 1225-1232. | 2.6 | 65 |
| 128 | ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma. Clinical Cancer Research, 2019, 25, 5859-5865. | 3.2 | 64 |
| 129 | Association of CYP1B1 Germ Line Mutations with Hepatocyte Nuclear Factor 1Î±â€“Mutated Hepatocellular Adenoma. Cancer Research, 2007, 67, 2611-2616. | 0.4 | 62 |
| 130 | Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Research, 2000, 60, 707-11. | 0.4 | 62 |
| 131 | Mapping of human chromosome 22 with a panel of somatic cell hybrids. Genomics, 1991, 9, 721-727. | 1.3 | 60 |
| 132 | The HOX gene network in hepatocellular carcinoma. International Journal of Cancer, 2011, 129, 2577-2587. | 2.3 | 60 |
| 133 | Genetics of hepatocellular carcinoma: The next generation. Journal of Hepatology, 2014, 60, 224-226. | 1.8 | 59 |
| 134 | Role of Contrast-Enhanced Sonography in Differentiation of Subtypes of Hepatocellular Adenoma: Correlation with MRI Findings. American Journal of Roentgenology, 2012, 199, 341-348. | 1.0 | 58 |
| 135 | Hepatocyte nuclear factor 1Î± suppresses steatosis-associated liver cancer by inhibiting PPARÎ³ transcription. Journal of Clinical Investigation, 2017, 127, 1873-1888. | 3.9 | 58 |
| 136 | Spectrum of HNF1A Somatic Mutations in Hepatocellular Adenoma Differs From That in Patients With MODY3 and Suggests Genotoxic Damage. Diabetes, 2010, 59, 1836-1844. | 0.3 | 57 |
| 137 | Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro. Clinical Cancer Research, 2017, 23, 4364-4375. | 3.2 | 57 |
| 138 | Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism. Hepatology, 2009, 50, 1871-1883. | 3.6 | 54 |
| 139 | Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. Journal of Hepatology, 2021, 74, 1155-1166. | 1.8 | 54 |
| 140 | Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. Journal of Hepatology, 2012, 56, 869-876. | 1.8 | 53 |
| 141 | Rnd3/RhoE Is down-regulated in hepatocellular carcinoma and controls cellular invasion. Hepatology, 2012, 55, 1766-1775. | 3.6 | 53 |
| 142 | Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer. Bioinformatics, 2018, 34, 3380-3381. | 1.8 | 53 |
| 143 | Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification. International Journal of Hepatology, 2013, 2013, 1-12. | 0.4 | 52 |
| 144 | Interethnic polymorphism of EWS intron 6: genome plasticity mediated by Alu retroposition and recombination. Human Genetics, 1997, 99, 357-363. | 1.8 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). OncoImmunology, 2015, 4, e1049804. | 2.1 | 51 |
| 146 | Identification of New Members of the Gas2 and Ras Families in the 22q12 Chromosome Region. Genomics, 1996, 38, 247-254. | 1.3 | 50 |
| 147 | p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer, 2010, 67, 23-30. | 0.9 | 50 |
| 148 | STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica, 2013, 98, 1748-1752. | 1.7 | 50 |
| 149 | p53 mutations in human tumors with chimericEWS/FLI/1 genes. International Journal of Cancer, 1994, 57, 336-340. | 2.3 | 49 |
| 150 | Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumors. Genes Chromosomes and Cancer, 1992, 5, 30-34. | 1.5 | 48 |
| 151 | Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma. American Journal of Pathology, 2011, 178, 881-894. | 1.9 | 48 |
| 152 | The liverâ€specific microRNAâ€122*, the complementary strand of microRNAâ€122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry. Hepatology, 2016, 64, 1623-1636. | 3.6 | 48 |
| 153 | Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making. Seminars in Liver Disease, 2014, 34, 363-375. | 1.8 | 47 |
| 154 | Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma. Oncogene, 2001, 20, 5232-5238. | 2.6 | 45 |
| 155 | Similar Tumor Suppressor Gene Alteration Profiles in Asbestos-Induced Murine and Human Mesothelioma. Cell Cycle, 2005, 4, 1862-1869. | 1.3 | 45 |
| 156 | VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib â€“ a multicentric retrospective analysis. Acta OncolÃ³gica, 2014, 53, 103-112. | 0.8 | 45 |
| 157 | Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. Modern Pathology, 2016, 29, 43-50. | 2.9 | 45 |
| 158 | BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. Journal of Hepatology, 2020, 72, 924-936. | 1.8 | 44 |
| 159 | Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. Hepatology, 2018, 68, 964-976. | 3.6 | 43 |
| 160 | The identification of small nodules in liver adenomatosis. Journal of Hepatology, 2003, 39, 77-85. | 1.8 | 42 |
| 161 | Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine and Growth Factor Reviews, 2015, 26, 499-506. | 3.2 | 42 |
| 162 | TGF-Î²1 promotes linear invadosome formation in hepatocellular carcinoma cells, through DDR1 up-regulation and collagen I cross-linking. European Journal of Cell Biology, 2016, 95, 503-512. | 1.6 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. Acta OncolÃ³gica, 2018, 57, 498-508. | 0.8 | 41 |
| 164 | Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. Cancer Discovery, 2021, 11, 2524-2543. | 7.7 | 41 |
| 165 | An adult male patient with multiple adenomas and a hepatocellular carcinoma: Mild Glycogen Storage Disease type Ia. Journal of Hepatology, 2010, 53, 213-217. | 1.8 | 40 |
| 166 | Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. OncoImmunology, 2013, 2, e27090. | 2.1 | 39 |
| 167 | Organization and expression of the Î»-like genes that contribute to the Î¼- Î˙ light chain complex in human pre-B cells. International Immunology, 1991, 3, 1081-1090. | 1.8 | 38 |
| 168 | LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor. , 1997, 18, 232-239. | | 38 |
| 169 | Note of caution: Contaminations of hepatocellular cell lines. Journal of Hepatology, 2017, 67, 896-897. | 1.8 | 37 |
| 170 | Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. Clinical Genitourinary Cancer, 2018, 16, e605-e612. | 0.9 | 37 |
| 171 | Expression of NKG2D ligands is downregulated by Î²-catenin signalling and associates with HCC aggressiveness. Journal of Hepatology, 2021, 74, 1386-1397. | 1.8 | 37 |
| 172 | Mapping of Human Î³-Glutamyl Transpeptidase Genes on Chromosome 22 and Other Human Autosomes. Genomics, 1993, 17, 299-305. | 1.3 | 36 |
| 173 | Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers. Oncogene, 2005, 24, 7253-7256. | 2.6 | 36 |
| 174 | Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma. Hepatology, 2019, 69, 160-178. | 3.6 | 36 |
| 175 | Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncology, The, 2022, 23, 161-171. | 5.1 | 36 |
| 176 | HNF1Î± inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines. BMC Cancer, 2011, 11, 427. | 1.1 | 35 |
| 177 | Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Mutagenesis, 2013, 28, 323-331. | 1.0 | 35 |
| 178 | Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. European Journal of Endocrinology, 2007, 156, 617-621. | 1.9 | 34 |
| 179 | Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2013, 25, 639-651. | 0.8 | 34 |
| 180 | Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical Genitourinary Cancer, 2019, 17, e981-e994. | 0.9 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Genetic alterations in hepatocellular adenomas: recent findings and new challenges. Journal of Hepatology, 2004, 40, 1036-1039. | 1.8 | 33 |
| 182 | Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics, 2007, 8, 997-1003. | 0.6 | 33 |
| 183 | Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. Molecular Therapy, 2016, 24, 660-661. | 3.7 | 33 |
| 184 | Assignment of the human stromelysin 3 (STMY3) gene to the q11.2 region of chromosome 22. Genomics, 1992, 13, 881-883. | 1.3 | 32 |
| 185 | Mutation of TP53 gene is involved in carcinogenesis of hepatic undifferentiated (embryonal) sarcoma of the adult, in contrast with Wnt or telomerase pathways: an immunohistochemical study of three cases with genomic relation in two cases. Journal of Hepatology, 2005, 42, 424-429. | 1.8 | 32 |
| 186 | Keratin 23 is a stress-inducible marker of mouse and human ductular reaction in liver disease. Journal of Hepatology, 2016, 65, 552-559. | 1.8 | 32 |
| 187 | Natural history of liver adenomatosis: A long-term observational study. Journal of Hepatology, 2019, 71, 1184-1192. | 1.8 | 32 |
| 188 | Absence ofKLF6gene mutation in 71 hepatocellular carcinomas. Hepatology, 2005, 41, 681-682. | 3.6 | 31 |
| 189 | Germline and somatic DICER1 mutations in familial and sporadic liver tumors. Journal of Hepatology, 2017, 66, 734-742. | 1.8 | 31 |
| 190 | Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia. Journal of Hepatology, 2018, 69, 1074-1087. | 1.8 | 31 |
| 191 | APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. OncoImmunology, 2019, 8, e1583547. | 2.1 | 31 |
| 192 | Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. Genome Medicine, 2021, 13, 113. | 3.6 | 31 |
| 193 | Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta OncolÃ³gica, 2014, 53, 1413-1422. | 0.8 | 30 |
| 194 | Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma. Cancer Research, 2021, 81, 4910-4925. | 0.4 | 30 |
| 195 | Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. Journal of Hepatology, 2022, 76, 343-352. | 1.8 | 30 |
| 196 | Focal nodular hyperplasia, hepatocellular adenomas: Past, present, future. Gastroenterologie Clinique Et Biologique, 2010, 34, 355-358. | 0.9 | 29 |
| 197 | Dinucleotide repeat polymorphism at the D22S268 locus. Human Molecular Genetics, 1993, 2, 336-336. | 1.4 | 28 |
| 198 | Hepatocellular adenoma displaying a HNF1Î± inactivation in a patient with familial adenomatous polyposis coli. Journal of Hepatology, 2006, 45, 883-886. | 1.8 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. Cancer Discovery, 2021, 11, 408-423. | 7.7 | 28 |
| 200 | The lncRNA H19-Derived MicroRNA-675 Promotes Liver Necroptosis by Targeting FADD. Cancers, 2021, 13, 411. | 1.7 | 28 |
| 201 | Characterisation of 16 polymorphic markers in theNF2 gene: Application to hemizygosity detection. Human Mutation, 1999, 13, 290-293. | 1.1 | 27 |
| 202 | Benign hepatocellular nodules: What have we learned using the patho-molecular classification. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 322-327. | 0.7 | 26 |
| 203 | LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naÃ¯ve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. Annals of Oncology, 2020, 31, S1157. | 0.6 | 26 |
| 204 | ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ÄŸ-catenin pathway. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 53-60. | 1.4 | 25 |
| 205 | Next-generationsequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors. OncoImmunology, 2012, 1, 1612-1613. | 2.1 | 24 |
| 206 | Frequent mutations of hepatocyte nuclear factor 1 in colorectal cancer with microsatellite instability. Gastroenterology, 2003, 124, 1311-1314. | 0.6 | 23 |
| 207 | Validation of <scp>VEGFR</scp>1 rs9582036 as predictive biomarker in metastatic clearâ€cell renal cell carcinoma patients treated with sunitinib. BJU International, 2016, 118, 890-901. | 1.3 | 23 |
| 208 | Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy. Clinical Cancer Research, 2022, 28, 540-551. | 3.2 | 23 |
| 209 | A framework for fibrolamellar carcinoma research and clinical trials. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 328-342. | 8.2 | 23 |
| 210 | Molecular Characterization of Germline NF2 Gene Rearrangements. Genomics, 2000, 65, 62-66. | 1.3 | 22 |
| 211 | Well-differentiated hepatocellular neoplasm of uncertain malignant potential. Human Pathology, 2015, 46, 634-635. | 1.1 | 22 |
| 212 | Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography. Gastroenterology, 2019, 157, 807-822. | 0.6 | 22 |
| 213 | Mutation of TCF1 encoding hepatocyte nuclear factor 1Î± in gynecological cancer. Oncogene, 2004, 23, 7588-7592. | 2.6 | 21 |
| 214 | The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma. Oncogene, 2021, 40, 127-139. | 2.6 | 21 |
| 215 | Hepatic resection for inflammatory hepatocellular adenomas: pathological identification of micronodules expressing inflammatory proteins. Liver International, 2010, 30, 149-154. | 1.9 | 20 |
| 216 | Fighting the bushfire in HCC trials. Journal of Hepatology, 2011, 55, 276-277. | 1.8 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transplantation, 2011, 17, S67-S71. | 1.3 | 20 |
| 218 | NRF2/KEAP1 and Wnt/Î²â€catenin in the multistep process of liver carcinogenesis in humans and rats. Hepatology, 2015, 62, 677-679. | 3.6 | 20 |
| 219 | DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. Hepatology, 2021, 74, 816-834. | 3.6 | 20 |
| 220 | Metalloproteinase meprin Î± regulates migration and invasion of human hepatocarcinoma cells and is a mediator of the oncoprotein Reptin. Oncotarget, 2017, 8, 7839-7851. | 0.8 | 20 |
| 221 | Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver International, 2022, 42, 492-506. | 1.9 | 20 |
| 222 | Overexpression of phosphatidylinositol 4-kinase type IIIÎ± is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma. BMC Cancer, 2014, 14, 7. | 1.1 | 19 |
| 223 | BRAF V600E mutations in bile duct adenomas. Hepatology, 2015, 61, 403-405. | 3.6 | 19 |
| 224 | RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. British Journal of Cancer, 2015, 113, 1313-1322. | 2.9 | 19 |
| 225 | Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. Communications Biology, 2021, 4, 166. | 2.0 | 19 |
| 226 | New insights in the management of Hepatocellular Adenoma. Liver International, 2020, 40, 1529-1537. | 1.9 | 18 |
| 227 | Delineation and candidate gene mutation screening of the 18q22 minimal region of deletion in head and neck squamous cell carcinoma. Oncogene, 2002, 21, 5016-5023. | 2.6 | 17 |
| 228 | Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas. Gut, 2020, 69, 1667-1676. | 6.1 | 17 |
| 229 | Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up. Radiology, 2020, 295, 361-372. | 3.6 | 17 |
| 230 | Deleting the Î²-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. Journal of Hepatology, 2022, 77, 424-435. | 1.8 | 17 |
| 231 | Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 1038-1046. | 1.8 | 17 |
| 232 | Neurofibromatosis type 2. European Journal of Cancer, 1994, 30, 1981-1987. | 1.3 | 16 |
| 233 | MicroRNAs Targeting HIF-2Î±, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2Î± Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma. Cancers, 2021, 13, 3099. | 1.7 | 16 |
| 234 | Comprehensive characterization of viral integrations and genomic aberrations in HBVâ€infected intrahepatic cholangiocarcinomas. Hepatology, 2022, 75, 997-1011. | 3.6 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Integrative Quantitative Proteomics Unveils Proteostasis Imbalance in Human Hepatocellular Carcinoma Developed on Nonfibrotic Livers. Molecular and Cellular Proteomics, 2014, 13, 3473-3483. | 2.5 | 15 |
| 236 | Characterization of a novel PXR isoform with potential dominant-negative properties. Journal of Hepatology, 2014, 61, 609-616. | 1.8 | 15 |
| 237 | A phosphokinomeâ€based screen uncovers new drug synergies for cancer driven by liverâ€specific gain of nononcogenic receptor tyrosine kinases. Hepatology, 2017, 66, 1644-1661. | 3.6 | 15 |
| 238 | Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. New England Journal of Medicine, 2018, 379, 1178-1180. | 13.9 | 15 |
| 239 | Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. JHEP Reports, 2022, 4, 100390. | 2.6 | 15 |
| 240 | Rapid isolation of cosmids from defined subregions by differential Alu-PCR hybridization on chromosome 22-specific library. Genomics, 1992, 13, 395-401. | 1.3 | 14 |
| 241 | Focal Î²â€catenin mutation identified on formalinâ€fixed and paraffinâ€embedded inflammatory hepatocellular adenomas. Histopathology, 2017, 71, 989-993. | 1.6 | 14 |
| 242 | PCR-Based Genotyping Can Generate Artifacts in LOH Analyses. BioTechniques, 1999, 27, 1100-1102. | 0.8 | 13 |
| 243 | Cryptic Exons as a Source of Increased Diversity of Ewing Tumor-Associated EWSâ€“FLI1 Chimeric Products. Genomics, 1999, 60, 371-374. | 1.3 | 13 |
| 244 | Malignant transformation of a Î² -catenin inflammatory adenoma due to an S45 Î² -cateninâ€“activating mutation present 12 years before. Human Pathology, 2017, 62, 122-125. | 1.1 | 13 |
| 245 | Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma. Lung Cancer, 2018, 126, 15-24. | 0.9 | 13 |
| 246 | NF2 gene deletion in a family with a mild phenotype. Journal of Medical Genetics, 2000, 37, 75-77. | 1.5 | 12 |
| 247 | Adeno-associated virus type 2 as an oncogenic virus in human hepatocellular carcinoma. Molecular and Cellular Oncology, 2016, 3, e1095271. | 0.3 | 12 |
| 248 | From the Editorâ€™s desk.... Journal of Hepatology, 2017, 66, 1-4. | 1.8 | 12 |
| 249 | Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. Acta OncolÃ³gica, 2021, 60, 1499-1506. | 0.8 | 12 |
| 250 | Cloning of the entire FL11 gene, disrupted by the Ewingâ€™s Sarcoma translocation breakpoint on 11q24, in a yeast artificial chromosome. Cytogenetic and Genome Research, 1994, 67, 129-136. | 0.6 | 11 |
| 251 | Will the pathomolecular classification of hepatocellular adenomas improve their clinical management?. Journal of Hepatology, 2011, 55, 8-10. | 1.8 | 11 |
| 252 | Double Heterozygous Germline HNF1A Mutations in a Patient With Liver Adenomatosis. Diabetes Care, 2012, 35, e35-e35. | 4.3 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Authorsâ€™ response: virusâ€“host interactions in HBV-related hepatocellular carcinoma: more to be revealed?. Gut, 2015, 64, 853-854. | 6.1 | 11 |
| 254 | Polymorphisms in the Von Hippelâ€“Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer, 2018, 16, 266-273. | 0.9 | 11 |
| 255 | Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 323-332. | 1.8 | 11 |
| 256 | Benign liver tumours: understanding molecular physiology to adapt clinical management. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 703-716. | 8.2 | 11 |
| 257 | Focal nodular hyperplasia with major sinusoidal dilatation: a misleading entity. BMJ Case Reports, 2010, 2010, bcr0920103311-bcr0920103311. | 0.2 | 10 |
| 258 | Synchronous hepatocellular carcinoma and Castleman's disease: The role of the interleukin-6-signaling pathway. Hepatology, 2012, 56, 392-393. | 3.6 | 10 |
| 259 | Primary Liver Carcinomas Can Originate From Different Cell Types: A New Level of Complexity in Hepatocarcinogenesis. Gastroenterology, 2013, 145, 53-55. | 0.6 | 10 |
| 260 | Hepatocellular adenoma with malignant transformation in a patient with neonatal portal vein thrombosis. Hepatology, 2016, 64, 675-677. | 3.6 | 10 |
| 261 | Genetic alterations in hepatocellular adenomas. Hepatology, 2003, 37, 480-480. | 3.6 | 9 |
| 262 | The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Frontiers in Immunology, 2011, 2, 66. | 2.2 | 9 |
| 263 | Prognostic factors of survival in <scp>HIV</scp>/<scp>HCV</scp> coâ€infected patients with hepatocellular carcinoma: The <scp>CARCINOVIC</scp> Cohort. Liver International, 2019, 39, 136-146. | 1.9 | 9 |
| 264 | MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma. Cancers, 2021, 13, 1554. | 1.7 | 9 |
| 265 | Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. Clinical Genitourinary Cancer, 2021, 19, e382-e394. | 0.9 | 9 |
| 266 | TGFÎ²â€induced FOXS1 controls epithelialâ€“mesenchymal transition and predicts a poor prognosis in liver cancer. Hepatology Communications, 2022, 6, 1157-1171. | 2.0 | 9 |
| 267 | Dual Blockade of Epidermal Growth Factor Receptorâ€“Induced Pathways: A New Avenue to Treat Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2012, 30, 1550-1552. | 0.8 | 8 |
| 268 | AAV2 and Hepatocellular Carcinoma. Human Gene Therapy, 2016, 27, 211-213. | 1.4 | 8 |
| 269 | From the Editorâ€™s desk.... Journal of Hepatology, 2018, 68, 1-4. | 1.8 | 8 |
| 270 | The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma. BMC Cancer, 2018, 18, 571. | 1.1 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). Clinical Nutrition, 2022, 41, 610-619. | 2.3 | 8 |
| 272 | Building a bridge between obesity, inflammation and liver carcinogenesis. Journal of Hepatology, 2010, 53, 777-779. | 1.8 | 7 |
| 273 | From the Editor's Desk .... Journal of Hepatology, 2015, 62, 6-7. | 1.8 | 7 |
| 274 | From the Editorâ€™s desk..... Journal of Hepatology, 2016, 64, 1-4. | 1.8 | 7 |
| 275 | Genomics of Viral Hepatitis-Associated Liver Tumors. Journal of Clinical Medicine, 2021, 10, 1827. | 1.0 | 7 |
| 276 | In situ hybridization of PCR amplified inter-Alu sequences from a hybrid cell line. Human Genetics, 1992, 88, 541-544. | 1.8 | 6 |
| 277 | Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice. Hepatic Oncology, 2015, 2, 291-302. | 4.2 | 6 |
| 278 | The transcriptomic G1â€“G6 signature of hepatocellular carcinoma in an Asian population. Medicine (United States), 2016, 95, e5263. | 0.4 | 6 |
| 279 | Human and mouse hepatocellular adenoma and carcinoma display similar tumorigenesis pathway alterations. Journal of Hepatology, 2008, 48, 884-886. | 1.8 | 5 |
| 280 | What's in a name?. Hepatology, 2009, 51, NA-NA. | 3.6 | 5 |
| 281 | From the Editorâ€™s desk.... Journal of Hepatology, 2017, 67, 1-4. | 1.8 | 5 |
| 282 | aCNViewer: Comprehensive genome-wide visualization of absolute copy number and copy neutral variations. PLoS ONE, 2017, 12, e0189334. | 1.1 | 5 |
| 283 | Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk. Annals of Oncology, 2018, 29, viii306-viii307. | 0.6 | 5 |
| 284 | MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. PLoS ONE, 2020, 15, e0238809. | 1.1 | 5 |
| 285 | AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro. American Journal of Physiology - Renal Physiology, 2021, 320, G543-G556. | 1.6 | 5 |
| 286 | Precise localization on chromosome 12 of the ATF-1 gene by fluorescence in situ hybridization. Human Genetics, 1994, 93, 207-8. | 1.8 | 4 |
| 287 | Single nucleotide polymorphisms in mRCCâ€”is their time up?. Nature Reviews Urology, 2015, 12, 424-426. | 1.9 | 4 |
| 288 | Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2019, 17, e235-e246. | 0.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERÎ± and HNF1Î±. Cancers, 2020, 12, 2213. | 1.7 | 4 |
| 290 | Genotypeâ€“Phenotype Relationships in Hepatocellular Carcinoma: p53 Inactivation Promotes Tumors With Stem Cell Features. Gastroenterology, 2012, 142, 1066-1069. | 0.6 | 3 |
| 291 | From the Editorâ€™s desk.... Journal of Hepatology, 2015, 63, 1-4. | 1.8 | 3 |
| 292 | Translating the molecular diversity of hepatocellular carcinoma into clinical practice. Molecular and Cellular Oncology, 2016, 3, e1057316. | 0.3 | 3 |
| 293 | RSPO2 abnormal transcripts result from read-through in liver tumours with high ÃŸ-catenin activation and CTNNB1 mutations. Gut, 2020, 69, 1152-1153. | 6.1 | 3 |
| 294 | Liver adenomatosis and NAFLD developed in the context of hereditary fructose intolerance. Liver International, 2020, 40, 3125-3126. | 1.9 | 3 |
| 295 | Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. JHEP Reports, 2022, 4, 100481. | 2.6 | 3 |
| 296 | LIM Homeobox-2 Suppresses Hallmarks of Adult and Pediatric Liver Cancers by Inactivating MAPK/ERK and Wnt/Beta-Catenin Pathways. Liver Cancer, 2022, 11, 126-140. | 4.2 | 3 |
| 297 | Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease. Hepatic Oncology, 2015, 2, 63-78. | 4.2 | 2 |
| 298 | From the Editorâ€™s desk.... Journal of Hepatology, 2016, 65, 1-4. | 1.8 | 2 |
| 299 | Cellular and Molecular Techniques. , 2018, , 88-110. | | 2 |
| 300 | Direct, indirect and total effect of HIV coinfection on the risk of nonâ€liverâ€related cancer in hepatitis C virusâ€infected patients treated by directâ€acting antivirals: a mediation analysis. HIV Medicine, 2021, 22, 924-935. | 1.0 | 2 |
| 301 | Characterisation of 16 polymorphic markers in the NF2 gene: Application to hemizygosity detection. Human Mutation, 1999, 13, 290. | 1.1 | 2 |
| 302 | Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma. European Urology Open Science, 2022, 40, 54-57. | 0.2 | 2 |
| 303 | R36: Sous-expression de Rnd3/RhoE dans le carcinome hÃ©patocellulaire : implication dans lâ€™invasion des hÃ©patocytes tumoraux. Bulletin Du Cancer, 2010, 97, S29-S30. | 0.6 | 1 |
| 304 | Comment on: How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?. Digestive and Liver Disease, 2010, 42, 234-235. | 0.4 | 1 |
| 305 | When activated oncogene meets immunity: A fight to prevent liver tumor initiation. Hepatology, 2012, 56, 387-389. | 3.6 | 1 |
| 306 | Physiopathology of Hepatocellular Carcinoma. , 2014, , 1881-1886. | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | P0266 : Adeno-Associated Virus 2 (AAV2) induces recurrent insertional mutagenesis in Human Hepatocellular Carcinomas. Journal of Hepatology, 2015, 62, S406. | 1.8 | 1 |
| 308 | Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2015, 13, e407-e410. | 0.9 | 1 |
| 309 | Genotype-Phenotype Correlation of CTNNB1 Mutations Reveals Different B-Catenin Activation Levels in Hepatocellular Tumors with High Activity Associated with Malignancy. Journal of Hepatology, 2016, 64, S578. | 1.8 | 1 |
| 310 | From the Editorâ€™s deskâ€¦. Journal of Hepatology, 2016, 65, 457-461. | 1.8 | 1 |
| 311 | From the Editorâ€™s desk.... Journal of Hepatology, 2017, 66, 1107-1110. | 1.8 | 1 |
| 312 | Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification. Journal of Hepatology, 2017, 66, S462. | 1.8 | 1 |
| 313 | From the Editorâ€™s desk..... Journal of Hepatology, 2017, 66, 671-674. | 1.8 | 1 |
| 314 | Reply. Hepatology, 2017, 66, 2093-2094. | 3.6 | 1 |
| 315 | From the Editorâ€™s desk.... Journal of Hepatology, 2018, 68, 1107-1109. | 1.8 | 1 |
| 316 | From the Editorâ€™s desk..... Journal of Hepatology, 2018, 69, 265-268. | 1.8 | 1 |
| 317 | PS-047-HSD17B13 loss of function variant protects from hepatocellular carcinoma developed on alcohol related liver disease. Journal of Hepatology, 2019, 70, e29-e30. | 1.8 | 1 |
| 318 | Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. Clinical Genitourinary Cancer, 2019, 17, e909-e912. | 0.9 | 1 |
| 319 | Journal of Hepatology: The Home of Liver Research, 2015â€“2019. Journal of Hepatology, 2019, 71, 1065-1069. | 1.8 | 1 |
| 320 | 686P Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial. Annals of Oncology, 2021, 32, S704. | 0.6 | 1 |
| 321 | Benign Liver Tumors. Molecular Pathology Library, 2011, , 769-775. | 0.1 | 1 |
| 322 | Prognostic Significance of SALL4 Expression Levels in Paediatric Acute Myeloid Leukaemia (AML).. Blood, 2008, 112, 2243-2243. | 0.6 | 1 |
| 323 | Genetic Alterations in the Chromosome 22q12 Region Associated with Development of Neuroectodermal Tumors. Cold Spring Harbor Symposia on Quantitative Biology, 1994, 59, 555-564. | 2.0 | 1 |
| 324 | Abstract 112: Genetic alterations in molecular tumor subgroups of malignant pleural mesothelioma. , 2016, , . | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Re: A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression. Journal of Urology, 2011, 186, 456-456. | 0.2 | 0 |
| 326 | Familial liver adenomatosis. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , . | 0.1 | 0 |
| 327 | From the Editorâ€™s deskâ€¦. Journal of Hepatology, 2015, 63, 775-777. | 1.8 | 0 |
| 328 | From the Editorâ€™s desk.... Journal of Hepatology, 2015, 63, 1057-1061. | 1.8 | 0 |
| 329 | From the Editorâ€™s desk.... Journal of Hepatology, 2015, 63, 1299-1302. | 1.8 | 0 |
| 330 | From the Editorâ€™s deskâ€¦. Journal of Hepatology, 2015, 62, 991-994. | 1.8 | 0 |
| 331 | P0265 : IGF2 is an oncogenic driver in HCC and emerges as a potential target for therapies. Journal of Hepatology, 2015, 62, S405-S406. | 1.8 | 0 |
| 332 | From the Editorâ€™s desk.... Journal of Hepatology, 2015, 62, 1221-1224. | 1.8 | 0 |
| 333 | P0480 : Role of the immune microenvironment during hepatocellular carcinoma. Journal of Hepatology, 2015, 62, S494. | 1.8 | 0 |
| 334 | From the Editorâ€™s desk.... Journal of Hepatology, 2015, 63, 537-539. | 1.8 | 0 |
| 335 | From the Editorâ€™s desk..... Journal of Hepatology, 2016, 65, 1073-1076. | 1.8 | 0 |
| 336 | Reply. Hepatology, 2016, 63, 342-342. | 3.6 | 0 |
| 337 | From the Editorâ€™s desk.... Journal of Hepatology, 2016, 64, 1199-1202. | 1.8 | 0 |
| 338 | From the Editorâ€™s desk.... Journal of Hepatology, 2016, 64, 759-762. | 1.8 | 0 |
| 339 | From the Editorâ€™s desk.... Journal of Hepatology, 2016, 65, 233-236. | 1.8 | 0 |
| 340 | From the Editorâ€™s desk.... Journal of Hepatology, 2016, 65, 657-660. | 1.8 | 0 |
| 341 | From the Editorâ€™s desk.... Journal of Hepatology, 2016, 65, 869-872. | 1.8 | 0 |
| 342 | Genomic Signatures of Risk Factors and Molecular Identification of HCC Subtypes. , 2016, , 113-119. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | From the Editorâ€™s desk.... Journal of Hepatology, 2016, 64, 991-995. | 1.8 | 0 |
| 344 | From the Editorâ€™s desk.... Journal of Hepatology, 2016, 64, 253-256. | 1.8 | 0 |
| 345 | From the Editorâ€™s desk.... Journal of Hepatology, 2016, 64, 527-531. | 1.8 | 0 |
| 346 | From the Editorâ€™s desk..... Journal of Hepatology, 2017, 66, 263-266. | 1.8 | 0 |
| 347 | From the Editorâ€™s desk.... Journal of Hepatology, 2017, 66, 469-472. | 1.8 | 0 |
| 348 | From the Editorâ€™s desk.... Journal of Hepatology, 2017, 67, 659-662. | 1.8 | 0 |
| 349 | From the Editorâ€™s desk.... Journal of Hepatology, 2017, 67, 889-892. | 1.8 | 0 |
| 350 | From the Editorâ€™s desk.... Journal of Hepatology, 2017, 67, 437-440. | 1.8 | 0 |
| 351 | From the Editorâ€™s desk.... Journal of Hepatology, 2017, 67, 207-210. | 1.8 | 0 |
| 352 | From the Editorâ€™s desk.... Journal of Hepatology, 2017, 67, 1125-1128. | 1.8 | 0 |
| 353 | From the Editorâ€™s desk.... Journal of Hepatology, 2018, 68, 377-379. | 1.8 | 0 |
| 354 | From the Editorâ€™s desk..... Journal of Hepatology, 2018, 68, 631-634. | 1.8 | 0 |
| 355 | From the Editorâ€™s desk.â€¦. Journal of Hepatology, 2018, 69, 1209-1212. | 1.8 | 0 |
| 356 | From the Editorâ€™s Deskâ€¦. Journal of Hepatology, 2018, 69, 759-761. | 1.8 | 0 |
| 357 | From the Editorâ€™s desk..... Journal of Hepatology, 2018, 69, 993-995. | 1.8 | 0 |
| 358 | Sigma 1 receptor: a potential actor in Hepato-Cellular Adenomas. Journal of Hepatology, 2018, 68, S48. | 1.8 | 0 |
| 359 | From the Editorâ€™s desk..... Journal of Hepatology, 2018, 68, 869-872. | 1.8 | 0 |
| 360 | AAV2 viral infection in liver and tumor development. Journal of Hepatology, 2018, 68, S664-S665. | 1.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Corrigendum to â€œFrom the Editorâ€™s Desk August 2018â€•[J Hepatol 69 (2018) 265â€“268]. Journal of Hepatology, 2018, 69, 987. | 1.8 | 0 |
| 362 | From the Editorâ€™s desk..... Journal of Hepatology, 2018, 69, 559-561. | 1.8 | 0 |
| 363 | From the Editorâ€™s deskâ€¦. Journal of Hepatology, 2019, 71, 231-234. | 1.8 | 0 |
| 364 | Advanced clear-cell renal cell carcinoma (accRCC): Association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome. Annals of Oncology, 2019, 30, v394-v395. | 0.6 | 0 |
| 365 | From the Editorâ€™s Deskâ€¦. Journal of Hepatology, 2019, 71, 853-855. | 1.8 | 0 |
| 366 | THU-456-Polyploidy spectrum: a new marker of molecular HCC tumour classification. Journal of Hepatology, 2019, 70, e360. | 1.8 | 0 |
| 367 | THU-374-The INCRNA H19-dervied MIR-675 promotes liver necroptosis by targeting fadd. Journal of Hepatology, 2019, 70, e318. | 1.8 | 0 |
| 368 | THU-445-Beta-catenin signaling controls NKG2D ligands expression in liver tumorigenesis. Journal of Hepatology, 2019, 70, e354-e355. | 1.8 | 0 |
| 369 | FRI-465-The INCRNA H19 is an oncogenic driver of HCC in chronic inflammation-mediated mouse model. Journal of Hepatology, 2019, 70, e601-e602. | 1.8 | 0 |
| 370 | THU-452-TFOX, a novel TGF-beta target gene, switches TGF-beta activity toward EMT during tumor progression of human hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e357-e358. | 1.8 | 0 |
| 371 | From the Editorâ€™s Deskâ€¦. Journal of Hepatology, 2019, 71, 641-644. | 1.8 | 0 |
| 372 | From the Editorâ€™s deskâ€¦. Journal of Hepatology, 2019, 70, 1039-1042. | 1.8 | 0 |
| 373 | JHEP Reports: A new EASL open access journal. JHEP Reports, 2019, 1, 1. | 2.6 | 0 |
| 374 | From the Editorâ€™s deskâ€¦. Journal of Hepatology, 2019, 71, 1-4. | 1.8 | 0 |
| 375 | From the Editorâ€™s deskâ€¦. Journal of Hepatology, 2019, 70, 583-586. | 1.8 | 0 |
| 376 | From the Editorâ€™s deskâ€¦. Journal of Hepatology, 2019, 70, 819-821. | 1.8 | 0 |
| 377 | From the Editorâ€™s desk..... Journal of Hepatology, 2019, 70, 335-338. | 1.8 | 0 |
| 378 | From the Editorâ€™s Deskâ€¦. Journal of Hepatology, 2019, 71, 1061-1064. | 1.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib. Kidney Cancer, 2020, 4, 139-149. | 0.2 | 0 |
| 380 | Gene Mutations and Transcriptomic Profiles Associated to Specific Subtypes of Hepatocellular Tumors. , 2010, , 259-275. | | 0 |
| 381 | Liver adenoma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , . | 0.1 | 0 |
| 382 | Abstract 5121: Acquired inactivating ARID2 mutations in lung non small cell carcinoma. , 2012, , . | | 0 |
| 383 | Abstract 1609: Proline-directed kinase signaling in human hepatocellular carcinomas developed on non-fibrotic liver. , 2014, , . | | 0 |
| 384 | Use of Molecular Biology for Identifying Benign Hepatocellular Tumors Leads to More Personalized Medicine. MD Conference Express, 2014, 14, 6-8. | 0.0 | 0 |
| 385 | Molecular subtypes and prognosis in RCC. Aging, 2015, 7, 219-220. | 1.4 | 0 |
| 386 | Abstract 2973: Exome sequencing of 243 liver tumors identifies new mutational signatures and potential therapeutic targets. , 2015, , . | | 0 |
| 387 | Abstract 919: Adeno-associated virus 2 (AAV2) induces recurrent insertional mutagenesis in human hepatocellular carcinomas. , 2015, , . | | 0 |
| 388 | Abstract IA20: Cancer subtypes and their immune microenvironments. , 2016, , . | | 0 |
| 389 | Abstract 3666: Co-occurring mutations of tumors suppressor genes, NF2 and LATS2, in malignant pleural mesothelioma. , 2016, , . | | 0 |
| 390 | Abstract 1257: A MYC-Aurka protein complex represents an actionable target in p53 altered liver cancer. , 2016, , . | | 0 |
| 391 | Abstract IA10: Tumor microenvironments: Prognostic and theranostic impacts. , 2016, , . | | 0 |
| 392 | Metastatic clear cell renal cell carcinoma: Proangiogenic gene expression and outcome on sunitinib.. Journal of Clinical Oncology, 2017, 35, e16085-e16085. | 0.8 | 0 |
| 393 | Re: Molecular Subtypes of Clear-Cell Renal Cell Carcinoma are Prognostic for Outcome after Complete Metastasectomy. Journal of Urology, 2019, 201, 664-665. | 0.2 | 0 |
| 394 | Structure, Dynamics, and Impact of Replication Stressâ€“Induced Structural Variants in Hepatocellular Carcinoma. Cancer Research, 2022, 82, 1470-1481. | 0.4 | 0 |